Infudopa IntraV
Advanced Parkinson's Disease
Pre-clinicalActive
Key Facts
About Dizlin Pharmaceuticals
Dizlin Pharmaceuticals is a private, pre-revenue biotech founded in 2003 (incorporated 2015) developing next-generation infusion therapies for advanced Parkinson's disease. Its lead assets, Infudopa SubC™ and Infudopa IntraV™, are stable liquid formulations of levodopa/carbidopa designed to provide continuous drug delivery, aiming to reduce debilitating 'on-off' symptoms. The company leverages academic collaborations and has entered a strategic global co-development agreement with Neuraxpharm, positioning it to advance its pipeline through partnership rather than building commercial infrastructure internally.
View full company profileTherapeutic Areas
Other Advanced Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Lecigon® (U.S. name not specified) | Intrance Medical Systems | Phase 3 |
| Lecigon | Lobsor Pharmaceuticals | Phase 3 |
| SER-252 (POZ-apomorphine) | Serina Therapeutics | Phase 1b |